UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
BioAssay record AID 698773 submitted by ChEMBL: Antithrombotic activity in Sprague-Dawley rat arteriovenous shunt model assessed as reduction of thrombus dry weight at 30 mg/kg, po qd for 5 consecutive days.
Click to buy DZ-313 New Head Strap with 360° Rotation Mount Adapter EVATH-340234 from TinyDeal.com with wholesale price and free shipping!
Bleeding disorders can be subdivided into three categories, including: Primary hemostasis disordersSecondary hemostasis disordersFibrinolysis disorders
Bleeding disorders can be subdivided into three categories, including: Primary hemostasis disordersSecondary hemostasis disordersFibrinolysis disorders
... Platelets have been mostly thought of as a fragment of a cell that stops bleeding and not much else. They can, also
BACKGROUND AND PURPOSE: We aimed to examine perfusion changes between 3 and 6 and 6 and 24 hours after stroke onset and their impact on tissue outcome. METHODS: Acute ischemic stroke patients underwent perfusion magnetic resonance imaging at 3, 6, and 24 hours after stroke onset and follow-up fluid-attenuated inversion recovery at 1 month to assess tissue fate. Mean transit time prolongation maps (MTTp=MTT-[median MTT of contralateral hemisphere]) were obtained at 3 (MTTp3 h), 6 (MTTp6 h), and 24 hours (MTTp24 h). Perfusion changes between 3 and 6 hours (ΔMTTp3_6) and 6 and 24 hours (ΔMTTp6_24) were calculated. A 2-step analysis was performed to evaluate the impact of ΔMTTp3_6 and ΔMTTp6_24 on tissue fate. First, a voxel-based multivariable logistic regression was performed for each individual patient with MTTp3 h, ΔMTTp3_6, and ΔMTT6_24 as independent variables and tissue fate as outcome. Second, Wilcoxon signed-rank tests on logistic regression coefficients were performed across patients ...
Note the typography of the following terms, which are found in descriptions of platelet hemostasis (use parenthetical abbreviated terms in accordance with , Abbreviations, Clinical, Technical, and Other Common Terms): See also , Blood Groups, Platelet Antigens, and Granulocyte Antigens, Platelet-Specific Antigens. |
Note the typography of the following terms, which are found in descriptions of platelet hemostasis (use parenthetical abbreviated terms in accordance with , Abbreviations, Clinical, Technical, and Other Common Terms): See also , Blood Groups, Platelet Antigens, and Granulocyte Antigens, Platelet-Specific Antigens. |
OKennedy, N., Crosbie, L., van Lieshout M., Broom J.L.. Webb D. and Duttaroy, A.K. (2006) Antiplatelet activity of tomato extract. Part I: Effects on platelet function in vitro and ex vivo - a time course cannulation study in healthy humans, Am. J. Clin Nutr 84:570-579 ...
Pathania YS, et al. Acral hemorrhagic blisters induced by reviparin. International Journal of Dermatology 58: 1329-1330, No. 11, Nov 2019. Available from: URL: http://doi.org/10.1111/ijd.14406 - IndiaCrossRefGoogle Scholar ...
Semantic Scholar extracted view of Continuous infusion of factor VIII concentrate to a patient with severe von Willebrand disease. by José Bruno Montoro et al.
We describe the first comparison of the effects of antagonists of different integrins on the arterial response to injury. These data indicate that continuous infusions of antagonists of either αIIbβ3 or αvβ3, started before and continued for 2 weeks after porcine PTCA, significantly reduce neointima formation at 28 days. αIIbβ3 inhibitors had marked effects on platelet aggregation and thrombus formation 6 hours after PTCA, whereas a selective αvβ3 inhibitor showed no effect. Equally, the αvβ3 inhibitors were able to inhibit VSMC adhesion, a property not shared by the selective αIIbβ3 inhibitor, although final reductions in neointima were comparable between the 3 treatment groups.. Both αIIbβ3 inhibition and combined αIIbβ3/αvβ3 inhibition induced rapid inhibition of ex vivo platelet aggregation, translating into concomitant reductions in adherent thrombus. Measurement of ex vivo platelet aggregation may overestimate the degree of platelet inhibition, and the relevance of this ...
There is evidence from recent studies that VEGF is stored in human megakaryocytes and is released from platelets on stimulation with thrombin.14 15 These studies were performed under in vitro conditions in the absence of important determinants of in vivo clotting such as the vessel wall, blood flow, and clotting proteases. Thus, it is uncertain if their in vitro observations are of relevance for the in vivo circumstances. The technique applied in our study covers many mechanisms relevant for hemostatic plug formation in vivo. It is performed directly on human subjects and takes into account the interaction between blood cells, endothelium, and various plasma proteins under physiological flow conditions. Thus, we believe that the experimental approach applied in this study is appropriate for investigating the mechanisms important for plug formation under conditions close to the in vivo circumstances.. The principal finding of our study was that much higher concentrations of VEGF are detectable in ...
Bodó, I. and Eikenboom, J. and Montgomery, R. and Patzke, J. and Schneppenheim, R. (2015) Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 13 (7). pp. 1345-1350. ISSN 1538-7933 ...
In the nanoscale assembly-based design of antithrombotic agents, poly-alpha,beta-DL-aspartyl-L-arginine (MW: 20 741) was prepared. from the thermal polycondensation of DL-aspartic acid and the amidation of polysuccimide with L-arginine. In the pH environments corresponding to the stomach (pH 1.2), intestinal tract (pH 7.6), blood and tissue fluids (pH 7.4) 4.8 x 10(4,2,-4,-6,-8) nM of poly-alpha,beta-DL-aspartyl-L-arginine assembled to form diverse nano-species. The sizes of the smallest nanoparticle, nanobell and nanomango were less than 100 nm. At the oral doses of 0.72, 1.44 and 2.89 mu mol kg(-1), poly-alpha,beta-DL-aspartyl-L-arginine dose-dependently inhibited the ex vivo platelet aggregation and the in vivo thrombosis of the treated rats. By assembling to form diverse nano-species, the absorption of oral poly-alpha,beta-DL-aspartyl-L-arginine in the stomach and intestinal tract could be assisted. ...
Ehlers-Danlos syndrome with Platelet Dysfunction from Fibronectin Abnormality information including symptoms, diagnosis, misdiagnosis, treatment, causes, patient stories, videos, forums, prevention, and prognosis.
Haemostatic effect of N8-GP when used for treatment of bleeding episodes and assessed as: Excellent, Good, Moderate, or None [ Time Frame: For the main phase (from 0-26 weeks of treatment) and the extension phase of the trial (from 26 weeks to the last patient has completed the trial ...
Haemostatic effect of N8-GP when used for treatment of bleeding episodes and assessed as: Excellent, Good, Moderate, or None [ Time Frame: For the main phase (from 0-26 weeks of treatment) and the extension phase of the trial (from 26 weeks to the last patient has completed the trial ...
Herbs for Antithrombotic. Definition of Antithrombotic Herbs. List of most effective herbs used as Antithrombotic in repertory format. Combinations of herbs are more effective than single herbs.
Platelets play a vital role in the blood-clotting process. One of the most common veterinary problems encountered with regard to platelets is von Willebrands disease (vWD), a disorder in dogs that is characterized by excessive bleeding due to a defect in platelet function ...
Recently, several von Willebrand factor gene mutations resulting in type IIA von Willebrands disease have been reported. We examined 8 patients from Sweden and Denmark with this phenotype and found two new candidate mutations and a hitherto unknown amino acid polymorphism. One patient had a de novo occurring mutation resulting in substitution of glycine for arginine 834. Previous reports have demonstrated conversion of arginine 834 to tryptophan or glutamine in IIA patients. A 2nd patient had a G(4825)--|A transition, substituting arginine for glycine 846. The transition produces a sequence congruent with that of the pseudogene but several lines of evidence indicate that a sequencing error due to influence by the latter could be excluded. The remaining 6 patients had one of the earlier described substitution mutations: Ser743--|Leu and Ile865--|Thr. In addition, two sequence variations not linked to the phenotype were found, namely Tyr821--|Cys and Val802--|Leu.
Objective: In order to correct the primary von Willebrand factor (VWF) defect and avoid supra-physiologic plasma levels of factor VIII, a pure VWF concentrate almost devoid of FVIII was developed and used in France since 1989. Methods: The pharmacokinetic (PK) profile of the most recent version of this concentrate (Wilfactin®; LFB, Les Ulis, France), treated with three virus-inactivation/removal methods (solvent/detergent, 35 nm filtration, dry heat treatment), was investigated in 25 patients. Seventeen patients with various types of clinically severe von Willebrand disease (VWD) were included in a crossover, randomized trial carried out in five European centers and comparing Wilfactin® with concentrates containing both FVIII and VWF (FVIII/VWF). Eight type 3 VWD patients were included in another trial carried out in six French centers comparing Wilfactin® with its previous version (Facteur Willebrand-LFB®; LFB) that adopted one virus-inactivation method only. Results: For both the ...
Von Willebrands disease, a common bleeding disorder affecting males and females equally, is usually inherited as a dominant trait.
Prediction of major adverse cardiovascular events (MACEs) may offer great benefits for patients with coronary artery disease (CAD). Von Willebrand factor (vWF) is stored in endothelial cells and released into blood plasma upon vascular dysfunction. This meta-analysis was performed to evaluate the prognostic value of plasma vWF levels in CAD patients with MACEs. A total of 15 studies were included in this meta-analysis through the search in PubMed, Embase and CNKI. Data were collected from 960 patients who had MACEs after CAD and 3224 controls nested without the adverse events. The standard mean difference (SMD) and 95% confidence intervals (95% CI) were calculated using random-effects model. The plasma vWF levels examined at 24 h and 48 h after admission were significantly higher in CAD patients with MACEs than those without. The pooled SMD among the MACEs group and the non-MACEs group was 0.55 (95% CI = 0.30-0.80, P | 0.0001) and 0.70 (95% CI = 0.27-1.13, P = 0.001), respectively. However, no
Acquired von Willebrands disease or syndrome (AVWS) is a rare bleeding disorder distinguished from congenital von Willebrands disease by age at presentation and absence of personal and family history of bleeding disorders. We report on 22 patients with AVWS seen over 25 years. Mean age at diagnosi …
The drug desmopressin (1-deamine-8-D-arginine vasopressin [DDAVP]) has become a mainstay of therapy for most patients with mild von Willebrand disease.
Thromboregulation is the series of mechanisms in how a primary clot is regulated. These mechanisms include, competitive inhibition or negative feedback. It includes primary hemostasis, which is the process of how blood platelets adhere to the endothelium of an injured blood vessel. Platelet aggregation is fundamental to repair vascular damage and the initiation of the blood thrombus formation. The elimination of clots is also part of thromboregulation. Failure in platelet clot regulation may cause hemorrhage or thrombosis. Substances called thromboregulators control every part of these events. One primary function of thromboregulation is the control of primary hemostasis, which is the platelet aggregation process. Some thromboregulators enhance platelet aggregation and some others inhibit the process. Platelet aggregation plays a critical role in the genesis of a resulting thrombus. Adhesion should remain local, but platelet aggregation must grow exponentially to form a platelet thrombus and ...
Dosing of mice with clopidogrel (50 mg/kg) completely inhibited ADP-induced ex vivo platelet aggregation and signaling (cAMP) and blocked all of the surface P2Y12 receptors on resting platelets. It is interesting to note that the same high dose of clopidogrel (50 mg/kg) prevented vascular occlusion but did not achieve the thrombotic profile associated with P2Y12 deficiency, whereas the direct-acting inhibitor elinogrel did recapitulate the profile of P2Y12(−/−) mice. Addition of elinogrel (1 mg/kg i.v.) to this clopidogrel regimen (50 mg/kg, 3 days) completely blocked the residual thrombosis, confirming that this process was mediated by P2Y12 receptors. On the basis of this data, we hypothesized that residual thrombosis observed in clopidogrel-treated mice might be due to an unblocked (intracellular) pool of P2Y12 exposed on the platelet surface after platelet activation in vivo. In this study, we demonstrated that an inducible pool of P2Y12 receptors exists in human and mouse platelets and ...
Most patients with vWD have mild disease that may go undiagnosed until trauma or surgery occurs. Trauma or surgery may result in life-threatening bleeding in severely affected individuals.
BioAssay record AID 444449 submitted by ChEMBL: Anticoagulant activity against Sprague-Dawley rat arterial thrombosis model induced by topical application of Fecl2.
Id like to go under the assumption that most of you know what Von Willebrands Disease is, but I realize that I wasnt very educated about it until recently and some of you reading this might not have VWD. VWD is a bleeding disorder with 3 types caused by a lack of the Von Willebrand Factor in your blood. The factor helps clot your blood and also carries factor 8 through your blood. In type 1, you simply dont have enough of it. In type 2, you also dont have enough of it, but there are several sub-types of type 2. I would try to further explain type 2, but it is highly complicated and given that I have type 1, I dont fully understand it. Type 3 is the most severe type of VWD, in this case, you do not have any of the Von Willebrand factor circulating through your blood. It is very rare to have type 3 because both of your parents must have VWD, of any type, in order for you to have type 3. And even if both of your parents have VWD, it doesnt mean youll end up with type 3 or VWD at all ...
s body exhumed in order to prove her case. We were told that my sister had died of coronary artery thrombosis, but she didnt have a history of heart disease, she said this week. There was no trace of alcohol or barbiturates in her system, but there was this brown cereal-type substance which was never identified. I believe she was killed because someone wanted to silence her. But who? Maxine admits that she has privately confronted the man she suspects of being responsible for her sisters death. ...
Diapharma公司为您提供Platelet Function Testing相关生物科研实验试剂Diapharma/Multiplate® Prostaglandin E1/MP0160/Kit/1ml + 5 micro test tubes的报价、+参数、MP0160图片、血小板功能检测特点、血小板功能检测咨询等有效信息,保证,是您网上购买Diapharma的放心代购平台
Platelet-fibrin thrombi in the lumen of atherostenotic carotid arteries may underlie transient ischemic attacks and cerebral infarction. For this reason, we investigated the antiplatelet and antithrombotic effects of a novel and potent platelet fibrinogen receptor (glycoprotein IIb/IIIa) antagonist (SK&F 106760).. The effects of 0.1-3.0 mg/kg i.v. SK&F 106760 on platelet aggregation were examined ex vivo in canine platelet-rich plasma (n = 20). In addition, the antithrombotic effects of SK&F 106760 were compared with those of aspirin in an acute canine model of extracranial carotid artery thrombosis with high-grade stenosis. Sham-operated (n = 4), vehicle-treated (n = 6), SK&F 106760-treated (n = 8), aspirin-treated (n = 9), and SK&F 106760+aspirin-treated (n = 5) dogs were examined.. The intravenous administration of SK&F 106760 caused a dose-related inhibition of ex vivo platelet aggregation. In the carotid artery thrombosis model, an occlusive thrombus formed at stenotic sites in the region ...
Background-Selective inhibitors of cyclooxygenase-2 (COX-2) increase the risk of myocardial infarction and thrombotic events, but the responsible mechanisms are not fully understood. Methods and Results-We found that ferric chloride-induced arterial thrombus formation was significantly greater in COX-2 knockout (KO) compared to wild type (WT) mice. Cross-transfusion experiments excluded the likelihood that COX-2KO platelets, despite enhanced aggregation responses to collagen and thrombin, are responsible for increased arterial thrombus formation in COX-2KO mice. Importantly, we observed that COX-2 deletion decreased prostacyclin (PGI2) synthase and production, proliferator-activated receptor (PPAR)δ and sirtuin-1 (SIRT1) expression, with consequent increased upregulation of tissue factor (TF), the primary initiator of blood coagulation. Treatment of WT mice with a PGI2 receptor (IP) antagonist or a PPARδ antagonist, which predisposes to arterial thombosis, decreased SIRT1 expression and ...
vWf is one of several endothelium derived haemostatic mediators, with key roles in platelet aggregation and stabilisation of circulating clotting factors.17 Large quantities of vWf are stored in the Weibel-Palade bodies of endothelial cells and can be mobilised rapidly after endothelial cell activation18 to result in transient increases of plasma vWf.10 In experimental models at least, endothelial dysfunction has been shown to promote thrombosis, vasospasm, and vessel occlusion.19 One recent study found increased concentrations of immunoreactive vWf in the endothelium over the endocardial cells lining the surface of human left atrial appendage in patients with cardiac disease and further found thrombus formation over sites exhibiting impaired endothelial function.20. Thus, persistently increased concentrations of vWf and endothelial damage and dysfunction pose a real risk to thrombosis. Indeed, our recent cross sectional study suggests a relation between vWf and risk stratification for stroke ...
TY - JOUR. T1 - Platelet function after cardiac surgery and its association with severe postoperative bleeding. T2 - the PLATFORM study. AU - for The Surgical and Clinical Outcome Research (SCORE) Group. AU - Ranucci, Marco. AU - Pistuddi, Valeria. AU - Di Dedda, Umberto. AU - Menicanti, Lorenzo. AU - De Vincentiis, Carlo. AU - Baryshnikova, Ekaterina. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Platelet dysfunction after cardiac surgery is a determinant of postoperative bleeding. The existing guidelines suggest the use of desmopressin and/or platelet concentrate transfusions in case of platelet dysfunction in bleeding patients, but no cut-off values for platelet activity exist in the literature. The Platelet Function in the Operating Room (PLATFORM) study aims to identify the relationship between platelet function after cardiopulmonary bypass and severe bleeding, finding adequate predictive values of platelet function for severe bleeding. The PLATFORM is a prospective cohort study on 490 adult patients ...
We studied a broad spectrum of platelet function parameters. Together with a low analytical variability for the various tests, a homogenous group of study subjects, and strictly standardized study conditions, these parameters would give a high sensitivity for detecting effects of infused epinephrine on platelet function.. Platelet count increased progressively with increasing arterial epinephrine in both EDTA- and ACD-anticoagulated blood, and the weight of circulating platelets increased by 29%, indicating recruitment of platelets into the circulation. Platelet size increased significantly in EDTA and decreased in ACD. The difference between EDTA and ACD was significant for both platelet count and size, suggesting that epinephrine not only recruits platelets into the circulation but also induces some microaggregation in vivo or adhesion ex vivo. Platelet aggregation in vitro induced by epinephrine decreased after infusion of epinephrine compared with saline but did not change when stimulated ...
2018 Elsevier Inc. All rights reserved. Transfusion medicine physicians and laboratory scientists are confronted daily with hemostasis and thrombosis-related concerns as they select and administer blood components, coagulation factor concentrates, anticoagulants, and agents to manage anticoagulant therapy. This chapter provides an introduction and overview of hemostasis. Primary hemostasis focuses on platelet function and interactions with the vasculature, endothelium, and the coagulation mechanism. Secondary hemostasis focuses on the coagulation cascade and is subdivided into the extrinsic, intrinsic, and common enzymatic pathways. Coagulation also includes control systems such as protein C, protein S, and antithrombin, and fibrinolysis. Depending on the defect, hemostasis disorders may be congenital or acquired, resulting in hemorrhage or thrombosis. The questions in this chapter will explore normal hemostasis, disorders of hemostasis, and the laboratory assays that predict, identify, and ...
It has been demonstrated that the umbilical cord matrix, represented by the Whartons Jelly (WJ), contains a great number of mesenchymal stem cells (MSCs), characterized by the expression of specific MSCs markers, shared by both human and animal models. The easy access to massive WJ amount makes it an attractive source of MSCs for cell-based therapies. However, as in other stem cell models, a deeper investigation of WJ-derived MSCs (WJ-MSCs) biological properties, probably modulated by their prolonged expansion and fast growth abilities, is required before their use in clinical settings. In this context, in order to analyze specific gene expression modifications occurring in WJ-MSCs, along with their culture prolongation, we investigated the transcriptomic profiles of WJ-MSCs after 4 and 12 passages of in vitro expansion by microarray analysis. Hierarchical clustering analysis of the data set originated from a total of 6 experiments revealed that in vitro expansion of WJ-MSCs up to 12 passages promote
Question - Trying to conceive, have platelet dysfunction in blood, getting heavy periods. Will it be transferred to baby?. Ask a Doctor about Fertility monitor, Ask an OBGYN, Maternal and Fetal Medicine
T cells are isolated from a patients blood and retrained, or "primed," to recognise tumour cells. They are then injected back into the patients bloodstream where they can now hunt and fight cancer.. There was some evidence that platelets might make cancer worse. For example, patients who have excessive clotting related to their cancer almost always have a worse prognosis, according to Li.. "Over the years, it has become appreciated that platelets are doing more than just clotting," says Li.. The first clue that cancer-fighting T cells might be suppressed by the bodys own clotting system came when the researchers gave melanoma to mice with genetically defective platelets.. Melanoma tumours grew much more slowly and primed T cells were much more active than in mice with normal platelets.. Next, the team isolated platelets and T cells from blood drawn from humans and mice.. In both cases, platelets with activated clotting activity suppressed T cell response.. It then used mass spectrometry to ...
Principal Investigator:TANI Kazuhiro, Project Period (FY):1996 - 1997, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Thoracic surgery
Arterial thrombosis is much less common than venous thrombosis, although it poses similar risks. The veins are responsible for taking blood and oxygen to different sections of the body. The blood is normally subject to higher pressure when it is travelling in the veins and may be moving more quickly. It is therefore less likely to clot in the arteries. Whereas venous thromboses normally lead to swelling and fluid congestion in an area, arterial thrombosis can lead to body tissue becoming starved of blood and oxygen. This can eventually lead to necrosis of the tissue. A thrombosis or embolism in the coronary artery can cause a heart attack. If blood supply to the brain is disrupted, the patient may suffer a stroke. ...
Dear Dr. Donohue: When I was 15, I had surgery and had blood tests. My doctor said there was a problem. He discovered I have a bleeding problem called von Willebrands disease. I am now 16, and even
... are conditions that prevent clotting elements in the blood, called platelets, from working as they should. Platelets help the blood clot. Congenital means present from birth.
Acetylsalicylic acid preparations specifically intended for use as antithrombotic agents are classified in this group. This exception from the basic principle of only one code for each route of administration is made because of the extensive use of acetylsalicylic acid both as an antithrombotic agent and as an analgesic. Whether an acetylsalicylic acid product should be classified in this group or in N02BA, should be decided at the national level based on the main indication of the product ...
Acetylsalicylic acid preparations specifically intended for use as antithrombotic agents are classified in this group. This exception from the basic principle of only one code for each route of administration is made because of the extensive use of acetylsalicylic acid both as an antithrombotic agent and as an analgesic. Whether an acetylsalicylic acid product should be classified in this group or in N02BA, should be decided at the national level based on the main indication of the product ...
In a previous paper (1) the organization of an experimental arterial thrombus in rat aorta during the first six days was described. The present paper will set out the thrombus organization during the following weeks and months. Within one month, fibrin and platelets inside the thrombus disappear, an …